PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR
作者机构：Department of Pharmaceutical SciencesCollege of Pharmacy and Health SciencesSt.John's UniversityQueensNY 11439USA
出 版 物：《Acta Pharmaceutica Sinica B》 (药学学报（英文版）)
年 卷 期：2014年第4卷第3期
页 面：202-207页
核心收录：
学科分类：1007[医学-药学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：This work was supported by funds from NIH(No.1R15CA143701) St.John's University Research Seed Grant(No.579-1110-7002)to Z.S.Chen
主 题：PD173074 ABCC10 Fibroblast growth factor receptor Multidrug resistance Tyrosine kinase inhibitor
摘 要：Multidrug resistance protein 7(MRP7,ABCC10)is a recently identified member of the ATP-binding cassette(ABC)transporter family,which adequately confers resistance to a diverse group of antineoplastic agents,including taxanes,vinca alkaloids and nucleoside analogs among *** studies indicate an increased MRP7 expression in non-small cell lung carcinomas(NSCLC)compared to a normal healthy lung *** studies revealed increased paclitaxel sensitivity in the Mrp7^(-/-)mouse model compared to their wild-type *** demonstrates that MRP7 is a key contributor in developing drug *** our group reported that PD173074,a specific fibroblast growth factor receptor(FGFR)inhibitor,could significantly reverse P-glycoprotein-mediated ***,whether PD173074 can interact with and inhibit other MRP members is *** the present study,we investigated the ability of PD173074 to reverse MRP7-mediated *** found that PD173074,at non-toxic concentration,could significantly increase the cellular sensitivity to MRP7 *** studies indicated that PD173074(1μmol/L)significantly increased the intracellular accumulation and in-turn decreased the efflux of paclitaxel by inhibiting the transport activity without altering expression levels of the MRP7 protein,thereby representing a promising therapeutic agent in the clinical treatment of chemoresistant cancer patients.
维普期刊数据库